Italy: Quince Therapeutics to acquire late-stage biotech company EryDel

Nasdaq-listed Quince Therapeutics, a biotech company focused on acquiring, developing, and commercializing innovative therapeutics, has entered into an agreement to acquire EryDel, an Italy-based, privately held, late-stage biotech company, in a stock-for-stock upfront exchange and potential downstream milestone cash payments. Upon completion, EryDel stockholders will own approximately 16.7% of the combined company and will be…

You must be a HMI Subscriber to view this content.

Subscribe Now »